David L. Ebel

Statistics

Publications

Citations

1.3K

H-Index

Active since

1972

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

KU Leuven

Pharmaceutical Product Development (United States)

International Biomedical (United States)

David L. Ebel is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, clinical pharmacology, and pharmacokinetics.

Publications per year

1972–2009

Publications

Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers

Anne Van Hecken, Jules I. Schwartz, Marleen Depré et al. · The Journal of Clinical Pharmacology · 2000 · 355 citations

Medicine, Pharmacology, Pharmacotherapy +13

Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet

Suzanne K. Swan, David W. Rudy, Kenneth C. Lasseter et al. · Annals of Internal Medicine · 2000 · 337 citations

Medicine, Pharmacology, Pharmacotherapy +12

Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in Humans

Stella Vincent, James R. Reed, Arthur Bergman et al. · Drug Metabolism and Disposition · 2007 · 152 citations

Medicine, Pharmacokinetics, Pharmacology +15

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics

Cuyue Tang, Magang Shou, Thomas H. Rushmore et al. · Pharmacogenetics · 2001 · 121 citations

Medicine, Pharmacokinetics, Pharmacology +16

Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers

Arthur Bergman, David L. Ebel, Fang Liu et al. · Biopharmaceutics & Drug Disposition · 2007 · 89 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

1–5 of 18